CleanSpark’s July 14th shift from Bitcoin miner to neo cloud is the core thesis: a $3.5B market cap now sits against a 20-year lease that starts at $6.6B and can reach $11.6B, with a separate Texas exclusivity window over 885 MW that could push contracted revenue far higher. The stock is framed as mispriced because markets still think in Bitcoin-miner terms even as leasing and data-center economics re-rate it toward infrastructure rent at near-100% margins. ENLV is the sponsored biotech counterpoint: Allocetra cleared FDA IND for a global phase 2B knee-osteoarthritis trial, with prior phase 1-2a data described as durable and statistically significant in older patients. The video closes on a risk-on setup with heavy short interest, a weak seasonal/macro backdrop, and a long-term bull case for CleanSpark if the pivot continues to execute.
APLD, NBIS, CRWV, and IREN ripped over the past year as neo-cloud names leased compute to hyperscalers in the billions, then sold off hard even after huge prior gains.
APLD was called a ZipTrader pick when it was priced at roughly 1/10 of its high valuation.
Markets initially ignored CLSK’s July 14 announcement because it was still being treated like a Bitcoin miner, while Bitcoin and crypto were described as out of season and neo-cloud spending remained in season.
CLSK’s July 14 Sandersville, Georgia deal is a 20-year triple-net lease with an unnamed high investment-grade global technology company for 175 MW of critical IT load, with first data hall delivery in Q4 2027.
The Sandersville lease is worth about $6.6B over the initial term and $11.6B if both five-year extensions are exercised, against a market cap of about $3.5B.
The Sandersville deal is expected to generate about $330M of average annual NOI at close to a 100% margin, with landlord build cost estimated at $10M-$12M per MW, or roughly $1.75B-$2.1B total CAPEX.
At $6.6B over 20 years across 175 MW, Sandersville implies about $1.9M per MW per year, described as a slight premium to comparable capacity.
The same tenant signed a letter of intent and exclusivity agreement covering CLSK’s entire Texas portfolio: 718 acres and up to 885 MW of secured and planned power across Sealy and Brazoria near Houston.
Matt Schultz said, 'I want to be clear that we are in an exclusivity window, not at a finish line,' signaling 885 MW of tied-up capacity that is not yet finalized.
At Sandersville-style pricing, 885 MW implies about $1.7B of annual lease revenue and roughly $33B over 20 years; adding Sandersville lifts contracted backlog near $40B and above $60B if all extensions are exercised.
CLSK is framed as a neo-cloud infrastructure play that sells the building and power while the tenant brings the computers and bears depreciation, power, maintenance, and inflation.
About 33% of CLSK float is reportedly short, described as one of the heaviest bearish positions in the AI trade.
Bitcoin miners are being hit because Bitcoin is in a bear market, while midterm years, August, and September are cited as weak seasonal periods and the Iran war is still ongoing.
ENLV’s Allocetra cleared FDA IND in March 2026 for a global, multicenter, randomized, double-blind, placebo-controlled phase 2B trial in age-related primary moderate-to-severe knee osteoarthritis.
Knee osteoarthritis affects more than 32 million Americans today, is projected to affect 78 million by 2040, and has no approved disease-modifying treatment; current care is pain management, steroid injections, or knee replacement.
ENLV’s completed phase 1-2a multicenter randomized double-blind study was reported to show a robust, durable, clinically meaningful, statistically significant effect, strongest in patients aged 60+ and improving over placebo at 3 months on pain and function.
Allocetra is an intra-articular immunomodulating cell therapy aimed at the underlying inflammatory process rather than masking pain, with the claimed goal of durable benefit.
Oren Hershcovitch said the FDA clearance is a step toward addressing a debilitating disease with poor treatment options and said the prior study showed a durable, clinically meaningful effect lasting at least 6 months.
Small-cap biotech dilution risk and trial failure risk were emphasized as high, and the investor-relations page was cited for further research.